Maarten de Groot, MolGen CEO, and Colin Denver, SpeeDx CEO
Maarten de Groot, MolGen CEO, and Colin Denver, SpeeDx CEO

Image source: MolGen/SpeeDx

Sample-to-answer workflow

Partnership for Covid-19 test solution

SpeeDx Pty, Ltd. and MolGen announced the signing of an agreement to collaborate on supply and distribution of clinical diagnostics products and instrumentation across Europe and Asia Pacific.

The partnership links specimen handling, nucleic acid extraction, assay set-up, amplification, and results reporting in a seamless integration of the companies technologies. “This partnership capitalises on the existing infrastructure of our two companies and the strength of our synergies,” said Colin Denver, SpeeDx CEO. “Our commitment to providing products and services that answer unmet clinical needs also extends to the pathology laboratories that are running our tests – in partnership with MolGen, we can address much of their workflow concerns and offer a more complete testing solution.”

Throughout the past year of Covid-19, in response to the increased demand for molecular testing workflow solutions, MolGen has developed a comprehensive offering including the PurePrep nucleic acid extraction portfolio, liquid handling instrumentation and other purpose-built automation to facilitate high-volume testing of SARS-CoV-2. SpeeDx complete the partnership with an initial offer of their CE-IVD SARS-CoV-2 test based on their proprietary PlexPCR technology, allowing pathology laboratories a single point of contact to fulfil their testing needs.

“For MolGen, the collaboration with SpeeDx is a perfect example of combining the best of both worlds. Our DNA and RNA extraction solutions and automated workflow perfectly pair with SpeeDx diagnostic assay technology” said Maarten de Groot, MolGen CEO. “During the Covid pandemic adding the CE-IVD SARS-CoV-2 assay to our diagnostics portfolio is great opportunity to start our collaboration. And this is only the beginning of jointly building an innovative product portfolio”.


Source: MolGen/SpeeDx

06.07.2021

Read all latest stories

Related articles

Photo

Early detection of coronavirus presence

Covid-19 wastewater testing: new quantification kit launched

Life science research and clinical diagnostics company Bio-Rad Laboratories announced the launch of its PREvalence ddPCR SARS-CoV-2 Wastewater Quantification Kit, a tool to detect the virus that…

Photo

Potential game-changer

Telling COVID-19 apart from influenza

Researchers have developed a diagnostic for SARS-CoV-2 that is capable of differentiating between COVID-19 and the garden-variety bug with fast turnaround.

Photo

Sponsored • DNA extraction chemistry

Providing innovative molecular workflows to empower future diagnostics

Founded in 2018 as a DNA extraction chemistry company, Dutch company MolGen entered the market operating within the agricultural sector. At first, the company’s founders, Maarten de Groot, Wim van…

Related products

Beckman Coulter – SARS-CoV-2 Assays

Immunoassays

Beckman Coulter – SARS-CoV-2 Assays

Beckman Coulter Diagnostics
CliniSys | MIPS – DaVinci

Information Technology

CliniSys | MIPS – DaVinci

CliniSys | MIPS Deutschland GmbH
Hamamatsu Photonics – NanoZoomer S60

Scanner

Hamamatsu Photonics – NanoZoomer S60

Hamamatsu Photonics Europe GmbH
i-Solutions Health – LabCentre

LIS, Middleware, POCT

i-Solutions Health – LabCentre

i-SOLUTIONS Health GmbH
Kugel medical – Grossing table UCS-2000-D-E

Grossing Station

Kugel medical – Grossing table UCS-2000-D-E

KUGEL medical GmbH & Co. KG
Subscribe to Newsletter